Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.93 USD | -9.98% | -.--% | +29.82% |
Apr. 18 | Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024 | |
Apr. 18 | Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | 239M 22.12M | Sales 2025 * | 343M 31.68M | Capitalization | 1.64B 151M |
---|---|---|---|---|---|
Net income 2024 * | -735M -67.96M | Net income 2025 * | -712M -65.84M | EV / Sales 2024 * | 8.82 x |
Net Debt 2024 * | 474M 43.83M | Net Debt 2025 * | 733M 67.81M | EV / Sales 2025 * | 6.92 x |
P/E ratio 2024 * |
-2.58
x | P/E ratio 2025 * |
-3.06
x | Employees | 166 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.64% |
Latest transcript on Hansa Biopharma AB
1 day | -9.98% | ||
3 months | -11.21% | ||
6 months | -2.33% | ||
Current year | +29.82% |
Managers | Title | Age | Since |
---|---|---|---|
Søren Tulstrup
CEO | Chief Executive Officer | 59 | 18-03-19 |
Hitto Kaufmann
CTO | Chief Tech/Sci/R&D Officer | 53 | Nov. 30 |
Achim Kaufhold
CTO | Chief Tech/Sci/R&D Officer | 66 | 20-05-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 73 | 18-05-28 | |
Peter Nicklin
CHM | Chairman | 61 | 22-06-29 |
Mats Blom
BRD | Director/Board Member | 59 | 19-05-21 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.69% | 47.86B | |
+46.90% | 41.42B | |
-3.46% | 40.66B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+28.07% | 12.14B | |
+0.17% | 12.15B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- HNSA Stock
- HNSBF Stock